North America Mini And Midi Horizontal Directional Drilling Market Size, Share & Trends Analysis Report By Machine Type, By Application, By Machine Size, By Parts Type, By Tooling, By End Use, By Region, And Segment Forecast, 2025 - 2030

North America Mini And Midi Horizontal Directional Drilling Market Size, Share & Trends Analysis Report By Machine Type, By Application, By Machine Size, By Parts Type, By Tooling, By End Use, By Region, And Segment Forecast, 2025 - 2030

Osteoarthritis Therapeutics Market Growth & Trends

The global osteoarthritis therapeutics market size is expected to reach USD 13.57 billion by 2030, registering a CAGR of 6.89% from 2025 to 2030, according to a new report by Grand View Research, Inc. The osteoarthritis therapeutics market is on the rise, driven by an increase in OA cases, especially among the aging population. In the U.S. alone, there are over 32.5 million OA patients, highlighting the demand for effective treatments. Ongoing research and development efforts are focused on creating new therapies, with a particular emphasis on understanding the disease and developing solutions to address its challenges.

Managing OA proves difficult owing to its dense tissue structure, but the introduction of novel drugs such as intra-articular drug administration has accelerated the development of targeted drug delivery. Researchers are actively exploring disease-modifying drugs and bioadaptive carriers to enhance the development of innovative osteoarthritis treatments. Market players are taking initiatives to contribute to market expansion, as seen with OrthoTrophix, Inc. presenting clinical data and a registration plan for TPX-100 for knee osteoarthritis at BIO 2022.

In addition, significant efforts are being made by key pharmaceutical companies and research institutes in realm of research and development, especially for disease-modifying osteoarthritis drugs. For instance, BioSenic's Phase 3 data presentation at the 2024 OARSI World Congress showcased the efficacy of JTA-004 in treating severe inflammatory knee osteoarthritis. The post hoc analysis concluded that JTA-004 is both safe and effective, offering targeted pain management for this specific subtype of condition. These advancements in targeted drug delivery and disease-modifying drugs, as demonstrated by presentations and positive trial results, are contributing to the expansion of the market for novel osteoarthritis treatments.

Moreover, the market for OA is experiencing significant growth owing to the introduction of personalized medications such as Bisphosphonates (anti-resorptive drugs) and Synvisc-ONE injection. In addition, pharmaceutical companies and research institutions are actively engaged in developing personalized treatments and cell-based therapies for OA. In December 2023, researchers at Columbia University made a breakthrough discovery of stem cells in adult mice capable of maintaining healthy cartilage in joints, with their decline contributing to OA development due to aging and injury.

Investing in this sector offers companies the opportunity to capitalize on evolving demands, thus gaining a competitive advantage. By leading innovative medication development, companies establish themselves as frontrunners, solidifying their position in the market. The advent of personalized OA medications and advancements in cell-based therapies are key drivers of market expansion, empowering companies to emerge as leaders in the field.

Osteoarthritis Therapeutics Market Report Highlights

• Based on drug type, the viscosupplementation agents segment accounted for the largest share of 37.06% in 2024 and is expected to grow at the fastest CAGR over the forecast period due to their adoption and efficacy in managing OA symptoms.
• Based on anatomy, the knee osteoarthritis (KOA) segment held a dominant share of 42.07% in 2024. KOA is one of the most common forms of chronic articular disease and OA worldwide and is characterized by high disability & morbidity rates.
• Based on route of administration, the parenteral route segment held a dominant share in 2024 and is expected to grow at a CAGR of 7.57% over the forecast period due to its efficacy for certain therapies, better pharmacokinetics and pharmacodynamics, ease of administration, and higher projected growth rate.
• Prescription drugs are poised to maintain dominance in the osteoarthritis therapeutics market' sales Channel segment in 2024.
• Based on end-use, the hospital pharmacies segment held a dominant share in 2024, accounting for 47.50%.
• North America osteoarthritis therapeutics market dominated the global industry and accounted for a 37.31% share in 2024. The North American market maintains its dominance due to several factors, including a high prevalence of obesity and supportive government policies.

Please note The report will be delivered in 2-3 business days upon order notification.